Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-NY008 PET Imaging in Multiple Myeloma
NCT05655676Phase 1Unknown
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 89Zr-NY008 in multiple myeloma (MM), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Evaluation of tissue distribution of 89Zr-NY008 at 7 days. Status: unknown.
02
Drugs
89Zr-NY008
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05655676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655676.